SCHEMBL3496830

SCHEMBL3496830

CC1CC2(CCCN(C(=O)OC(C)(C)C)C2)C(=O)N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
THRB P10828 1/20 0.39
USP30 Q70CQ3 1/20 0.39
HPGD P15428 1/20 0.39
DDB1 Q16531 2/20 0.37
CRBN Q96SW2 2/20 0.37
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
EPHX2 P34913 1/20 0.36
NR1H2 P55055 1/20 0.36
MKNK1 Q9BUB5 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
USP2 O75604 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MMP2 P08253 1/20 0.35
MMP13 P45452 1/20 0.35
MMP14 P50281 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20608080 0.93 USP30 (0.45) MAPTKDM4ETHRBUSP30DDB1
SCHEMBL15449852 0.85 KDM4E (0.42) MAPTKDM4ETHRBUSP30HPGD
SCHEMBL15437685 0.85 KDM4E (0.42) MAPTKDM4ETHRBUSP30HPGD
SCHEMBL15449851 0.85 KDM4E (0.42) MAPTKDM4ETHRBUSP30HPGD
SCHEMBL30801695 0.80 USP30 (0.42) MAPTKDM4ETHRBUSP30HPGD
SCHEMBL30793093 0.79 CRBN (0.45) MAPTKDM4ETHRBUSP30HPGD
SCHEMBL1207913 0.79 USP30 (0.41) MAPTKDM4ETHRBUSP30HPGD
SCHEMBL3496505 0.79 USP30 (0.41) MAPTKDM4ETHRBUSP30HPGD
SCHEMBL3497223 0.78 ACACB (0.43) MAPTKDM4ETHRBUSP30HPGD
SCHEMBL29346927 0.78 CRBN (0.43) MAPTKDM4ETHRBUSP30HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160255-A1 SPIRO-CYCLIC COMPOUND ACACA, CPT1B, PC MAPT 4356/4885KDM4E 1730/4885THRB 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.